Ongoing Task Forces

- AllergoOncology

AO Logo vector-2-web


The term AllergoOncology (AO) describes the interesting interface between allergies, IgE responses, and Th2 immunity, with cancer development. The establishment of a Task Force on this exciting and continuously evolving topic in EAACI is timely and appropriate. Previous AO activities have included a milestone position paper (Allergy, 2008), two International Conferences on AllergoOncology, a book initiative, “IgE and Cancer” (Humana Press, Springer, 2010), and a key Symposium-in-Writing initiative incorporating 10 peer-reviewed manuscripts on AllergoOncology published by key researchers in the field (Cancer Immunology, Immunotherapy, 2012)

The AO task force aims to serve as an interphase between the disciplines of oncology, allergy and Th2 immunity. The topics of this AO Task Force session will cover basic, translational and clinical research, and will also encompass epidemiology, comparative oncology research, clinical observations and clinical studies, including novel vaccination and immunotherapy approaches harnessing IgE functions to target cancer. This important endeavor will bring basic, clinical scientists and clinicians together interested in the interdisciplinary links between allergies and cancer and will support interdisciplinary links, exchange of knowledge and advances in both fields. At present, this is the first AO platform worldwide.

See our position papers "AllergoOncology – the impact of allergy in oncology: EAACI position paper" and "AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer“.

Aims:
  • To establish a platform for regular exchange of scientific achievements in the AO area.
  • To bring basic, clinical scientists and clinicians together interested in the interdisciplinary approach between allergies and cancer.
  • To cover educational aspects, by e.g. organizing workshops, Spring Schools and poster-workshops with students and medical trainees as the main targets, and to also engage with clinically-active colleagues and clinical scientists.
  • To actively and regularly communicate scientific advances and achievements of the field.
  • To engage with oncology societies with the aim of attaching AO satellite symposia and workshops to them.

IO-meeting
Pre-TaskForce Meeting at EAACI annual conference in Copenhagen, Denmark, 2014 - From left to right: Hannah Gould, Judit Fazekas, Sophia Karagiannis, Erika Jensen-Jarolim, Josef Singer, Jozef Janda, Melanie Plum, Edzard Spillner
 
PPP3 Graph 2018
The faculty of the AllergoOncology Task Force meeting has continuously grown until 2018

Find our list of experts here.
Last updated 20 June 2018
Privacy Policy - disclaimer

EAACI recently updated its privacy policy and would like to highlight some key bits of information with you.

  • EAACI does not distribute, share or sell your information;
  • For technical and administrative purposes some information that can be used to identify you may be forwarded to third parties. For example, to process your registration for the EAACI Annual Congress and other EAACI events;
  • The Academy may also send you e-mail messages with news from the society. If you would like to no longer receive them, you can unsubscribe at any time by using the unsubscribe link in any of our communications;
  • You may also update your preferences or your profile information at any time by contacting us.

To continue please confirm that you agree with our updated privacy policy.

Thank you!

You have successfully agreed the new privacy policy – disclaimer.

Thank you!

You disagreed with the new privacy policy – disclaimer and your feedback will be reviewed as soon as possible.

Agree & Continue
Disagree
Send feedback
Cancel